Recurrent Oral Cancer and Salvage Options

  • Joshua E. LubekEmail author
  • Michael Nagai


Recurrence rates for oral squamous cell cancer are reported to occur in up to 30% of patients depending on initial disease stage presentation with most recurrences developing either locally or regionally within 3 years of initial therapy. Successful salvage therapy for recurrent disease will depend on numerous factors to include initial tumor staging and pathologic features, location and timing of recurrence, and initial treatment strategy rendered. This chapter will review current literature on the etiology, prognosis, and various treatment options available with regard to management of recurrent oral squamous cell carcinoma.


Oral cancer Recurrent cancer Salvage surgery Neck surgery 


  1. 1.
    National Cancer Institute. Surveillance, epidemiology and end results program. cancer stat facts: oral cavity and pharynx cancer.
  2. 2.
    Patel SC, Carpenter WR, Tyree S, Couch ME, Weissler M, Hackman T, et al. Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years. J Clin Oncol. 2011;29:1488–94.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Farquhar DR, Tanner AM, Masood MM, et al. Oral tongue carcinoma among young patients an analysis of risk factors and survival. Oral Oncol. 2018;84:7–11.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Hussein AA, Helder MN, de Visscher JG, et al. Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: a systematic review. Eur J Cancer. 2017;82:115–27.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Haas I, Hauser U, Ganzer U. The dilemma of follow-up in head and neck cancer patients. Eur Arch Otorhinolaryngol. 2001;58:177–83.CrossRefGoogle Scholar
  6. 6.
    Ho AS, Kraus DH, Ganly I, et al. Decision making in the management of recurrent head and neck cancer. Head Neck. 2014;36:144–51.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Eckardt A, Barith EL, Kokemueller H, et al. Recurrent carcinoma of the head and neck: treatment strategies and survival analysis in a 20-year period. Oral Oncol. 2004;40:427–32.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Liao CT, Chang JT, Wang HM, et al. Salvage therapy in relapsed squamous cell carcinoma of the oral cavity: how and when? Cancer. 2008;112:94.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Ord RA, Kolokythas A, Reynolds MA. Surgical salvage for local and regional recurrence in oral cancer. J Oral Maxillofac Surg. 2006;64:1409–14.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope. 2000;110:1–18.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Warren S, Gates DC. Multiple malignant primary tumors: a survey of the literature. Am J Cancer. 1932;16:1358–414.Google Scholar
  12. 12.
    Ord RA, Isaiah A, Dyalram D, Lubek JE. Is long term follow up mandatory for stage I oral tongue cancer? J Oral Maxillofac Surg. 2018;76:2676–83. Scholar
  13. 13.
    Schwartz GJ, Mehta RH, Wenig BL, et al. Salvage treatment for recurrent squamous cell carcinoma of the oral cavity. Head Neck. 2000;22:34–41.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Liu SA, Wong YK, Lin JC, et al. Impact of recurrence interval on survival of oral cavity squamous cell carcinoma patients after local relapse. Otolaryngol Head Neck Surg. 2007;136:112–8.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Brandwein-Gensler M, Teixeira MS, Lewis CM, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol. 2005;29:167.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Matsuura D, Valim TD, Kulcsar MAV, et al. Risk factors for salvage surgery failure in oral cavity squamous cell carcinoma. Laryngoscope. 2018;128:1113–9.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Kligerman J, Lima RA, Soares JR, et al. Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of the oral cavity. Am J Surg. 1994;168:391.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    D’Cruz AK, Vaish R, Kapre N, et al. Elective versus therapeutic neck dissection in node negative oral cancer. N Engl J Med. 2015;373:521.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Anderson CR, Sisson K, Moncrieff M. A meta-analysis of margin size and local recurrence in oral squamous cell carcinoma. Oral Oncol. 2015;51:464–9.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Shah A. Postoperative pathologic assessment of surgical margins in oral cancer a contemporary review. J Oral Maxillofac Pathol. 2018;22:78–85.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Sopka DM, Li T, Lang MN, et al. Dysplasia at the margin? Investigating the case for subsequent therapy in ‘low-risk’ squamous cell carcinoma of the oral tongue. Oral Oncol. 2013;49(11):1083–7.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Pu Y, Wang Y, Huang X, et al. The influence of mild dysplasia at the surgical margin on the prognosis of oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2016;45:1372–7.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Gokavarapu S, Parvataneni N, Pavagada S, et al. Mild to moderate dysplasia at surgical margin is significant indicator of survival in patients with oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123:330–7.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Cocks H, Ah-See K, Capel M, et al. Palliative and supportive care in head and neck cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol. 2016;130:198–207.CrossRefGoogle Scholar
  25. 25.
    Kim J, Kim S, Albergotti W, et al. Selection of ideal candidates for surgical salvage of head and neck squamous cell carcinoma: effects of the Charlson age comorbidity index and oncologic characteristics on a 1-year survival and hospital course. JAMA Otolaryngol Head Neck Surg. 2015;141:1059–65.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Lok BH, Jiang G, Gutiontov S, et al. Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. Oral Oncol. 2015;51:957–62.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Cheung PK, Chin RY, Eslick GD. Detecting residual/recurrent head neck squamous cell carcinomas using PET or PET/CT systematic review and meta analysis. Otolaryngol Head Neck Surg. 2016;154:421–32.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Lin HC, Kang CJ, Huang SF, et al. Clinical impact of PET/CT imaging after adjuvant therapy in patients with oral cavity squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2017;44:1702–11.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Wong LY, Wei WI, Lam LK, Yuen AP. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003;25:953–9.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Mizrachi A, Migliacci JC, Montero PE, et al. Neck recurrence in clinically node negative oral cancer: 27 year experience at a single institution. Oral Oncol. 2018;78:94–101.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Skelenica S, Gardiner S, Dierks EJ, et al. Survival analysis and risk factors for recurrence in oral squamous cell carcinoma does surgical salvage affect outcome. J Oral Maxillofac Surg. 2010;68:1270–5.CrossRefGoogle Scholar
  32. 32.
    Gilbert H, Kagan AR. Recurrence patterns in squamous cell carcinoma of the oral cavity, pharynx and larynx. J Surg Oncol. 1974;6:357–80.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Knoetgen J, Choudry U, Finical SJ, et al. Head and neck reconstruction with a second free flap following resection of a recurrent malignance. Ann Plast Surg. 2005;55:378–83.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Smirk R, Kyzas P. Outcome of salvage procedures for recurrent oral and oropharyngeal cancer. Br J Oral Maxillofac Surg. 2018;56:847–53.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Kostrzewa JP, Lancaster WP, Iseli TA, et al. Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer. Laryngoscope. 2010;120:267–72.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Rosenthal DI, Mohamed ASR, Garden AS, et al. Final report of a prospective randomized trial to evaluate the dose response relationship for postoperative radiation therapy and pathologic risk groups in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2017;98:1002–11.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Hosni A, Huang SH, Chiu K, Xu W, Su J, Bayley A, Bratman SV, Cho J, Giuliani M, Kim J, O’Sullivan B, Ringash J, Waldron J, Spreafico A, Yu E, de Almeida JR, Monteiro E, Chepeha DB, Irish JC, Goldstein DP, Hope A. Predictors of early recurrence prior to planned post-operative radiation therapy for oral cavity squamous cell carcinoma and outcomes following salvage intensified radiation therapy. Int J Radiat Oncol Biol Phys. 2019, 103:363–73. Scholar
  38. 38.
    Rosenthal DI, Liu L, Lee JH, et al. Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck. 2002;24:115–26.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    McDonald MW, Lawson J, Garg MK, et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology head and neck cancer. Int J Radiat Oncol Biol Phys. 2011;80:1292.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Sulman EP, Schwartz DL, Le TT, et al. IMRT reirradiation of head and neck cancer – disease control and morbidity outcomes. Int J Radiat Oncol. 2009;73:399–409.CrossRefGoogle Scholar
  41. 41.
    Caudell JJ, Ward MC, Riaz N, et al. Volume, dose and fractionation considerations for IMRT based reirradiation in head and neck cancer: a multi-institution analysis. Int J Radiat Oncol Biol Phys. 2018;100:606–17.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Merlotti A, Mazzola R, Alterio D, et al. What is the role of post operative re-irradiation in recurrent and second primary squamous cell cancer of the head and neck? A literature review according to PICO criteria. Crit Rev Oncol Hematol. 2017;111:20.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Popovtzer A, Gluck I, Chepeha DB, et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys. 2009;74:1342–7.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Phan J, Sio TT, Nguyen TP, et al. Reirradiation of head and neck cancers with proton therapy: outcomes and analysis. Int J Radiat Oncol bio Phys. 2016;96:30–41.CrossRefGoogle Scholar
  45. 45.
    Romesser PB, Cahlon O, Scher ED, et al. Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. Int J Radiat Oncol Bio Phys. 2016;95:386–95.CrossRefGoogle Scholar
  46. 46.
    Chen AM, Vaughn A, Narayan S, et al. Palliative radiation therapy for head and neck cancer: toward an optimal fractionation scheme. Head Neck. 2008;30:1586–91.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Corry J, Peters LJ, Costa ID, et al. The ‘QUAD SHOT’—a phase II study of palliative radiotherapy for incurable head and neck cancer. Radiother Oncol. 2005;77:137–42.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Jacob C, Layman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10:257–63.CrossRefGoogle Scholar
  49. 49.
    Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30:281–8.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Vermorkin JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.CrossRefGoogle Scholar
  51. 51.
    Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a southwest oncology group study. J Clin Oncol. 1992;10:1245.CrossRefGoogle Scholar
  52. 52.
    Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab vs investigators choice in recurrent metastatic squamous cell carcinoma of the head and neck: 2 year long term survival update of CheckMate 141 with analyses by PD-L1 expression. Oral Oncol. 2018;81:45–51.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Hsu C, Lee S-H, Ejadi S, et al. Antitumor activity and safety of pembrolizumab in patients with PD-L1 positive nasopharyngeal carcinoma: interim results from a phase 1b study. Ann Oncol. 2015;26:93–102.Google Scholar
  54. 54.
    Outh-Gauer S, Alt M, Le Tourneau C, et al. Immunotherapy in head and neck cancers: a new challenge for immunologists, pathologists and clinicians. Cancer Treat Rev. 2018;65:54–64.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Oral-Head and Neck Surgery/Microvascular Reconstructive Surgery, Department of Oral and Maxillofacial SurgeryUniversity of MarylandBaltimoreUSA
  2. 2.Oral-Head and Neck Surgery/Microvascular SurgeryUniversity of MarylandBaltimoreUSA

Personalised recommendations